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1. Introduction
Viral vectors have been widely used to deliver several therapeutic genes in the clinical ap‐
proach of gene therapy. The lentiviral vector permits stable and efficient gene transfer into
non-dividing cells in the central nervous system of neurological and neurodegenerative dis‐
eases (Deeks, et al., 2002; Mavilo, et al., 2006; Rossi et al., 2007; Ciceri, et al., 2009; Naldini,
2011). Moreover, long-term expression of delivered gene attributed to genome integration
has an advantage not only for clinical application, but also for gene therapy trials in animal
models (Naldini et al., 1996; Reiser et al., 1996; Mochizuki et al., 1998; Mitrophanous et al.,
1999; Wong et al., 2006; Lundberg et al., 2008). Among many lentiviral vector systems, the
most familiar is the human immunodeficiency virus type-1 (HIV-1)-based vector of which
molecular biological property has been extensively studied (Rabson and Martin, 1985; Joshi
and Joshi, 1996; Nielsen et al., 2005; Pluta and Kacprzak, 2009).
Axonal transport in the retrograde direction, as observed in the case of some viral vectors,
has a considerable advantage for transferring genes into neuronal cell bodies situated in re‐
gions remote from the injection sites of the vectors (see Fig.1). These viral vectors, for exam‐
ple, injected into the striatum, transfer the genes via retrograde transport into nigrostriatal
dopaminergic neurons, which are the major target for gene therapy of Parkinson’s disease
(Zheng et al., 2005; Barkats et al., 2006). Intramuscular injection of the vectors also delivers
retrogradely the genes into motor neurons that are the target for gene therapy of motor neu‐
ron diseases (Baumgartner & Shine, 1998; Perrelet et al., 2000; Mazarakis et al., 2001; Saka‐
moto et al., 2003; Azzouz et al., 2004).
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In our previous study, we generated an HIV-1-based vector pseudotyped with a variant of
rabies virus glycoprotein (RV-G) gene and tested gene transfer through retrograde axonal
transport into several brain regions (Kato et al., 2007). Although this pseudotyped vector
showed gene transfer through retrograde transport in the rodent and nonhuman primate
brains, higher titer stocks of the vector was required for the application of gene therapy tri‐
als. To enhance the efficiency of retrograde gene transfer, we subsequently developed a nov‐
el type of lentiviral vector that shows highly efficient retrograde gene transfer (HiRet) by
pseudotyping an HIV-1-based vector with fusion glycoprotein B type (FuG-B) composed of
parts of RV-G and vesicular stomatitis virus glycoprotein (VSV-G) (Kato et al., 2011a,b).
More recently, we developed another vector system for neuron-specific retrograde gene
transfer (NeuRet) by pseudotyping the HIV-1-based vector with fusion glycoprotein C type
(FuG-C) composed of a different set of parts of RV-G and VSV-G (Kato et al., 2011c). Inter‐
estingly, the NeuRet vector shows high efficiency of retrograde gene transfer into various
neuronal populations, whereas it remarkably reduces gene transduction into dividing cells
including glial and nerural stem/progenitor cells around the vector injection sites. One sig‐
nificant issue on the therapeutic use of lentiviral vectors is transgene integration into the
host genome in dividing cells, which may lead to tumorigenesis by altering the expression
of proto-oncogenes adjacent to the integration sites (De Palma et al., 2005; Themis et al.,
2005; Montini et al., 2006). In this context, the NeuRet vector can reduce the risk of vector
transduction into dividing cells in the brain and improve the safety of future gene therapy
trials for neurological and neurodegenerative disorders.
Figure 1. Gene transfer process through retrograde axonal transport.
Gene Therapy - Tools and Potential Applications388
The viral vectors enter nerve terminals and are retrogradely transported through axons into
neuronal cell bodies, resulting in the induction of transgene expression.
In this chapter, we recapitulate gene transduction property of the HiRet and NeuRet vectors,
and then describe the application of the NeuRet vector for retrograde gene transfer into the
nigrostriatal dopamine system in nonhuman primates.
2. Gene transduction property of HiRet and NeuRet vectors
2.1. HiRet vector
The HiRet vector is a pseudotype of the HIV-1 lentiviral vector with FuG-B, which is com‐
posed of the extracellular and transmembrane domains of RV-G (challenged virus standard
strain) and the cytoplasmic domain of VSV-G (Fig. 2A) (Kato et al., 2011a). When the HiRet
vector encoding green fluorescent protein (GFP) was injected into the dorsal striatum of
mice, we observed high efficiency of retrograde gene transfer into the brain regions inner‐
vating the striatum, including the primary motor cortex (M1), primary somatosensory cortex
(S1), parafascicular nucleus (PF) in the thalamus, and substantia nigra pars compacta (SNc)
in the ventral midbrain (Fig. 2B). The extent of gene transfer efficiency increased compared
with that of the RV-G pseudotype, ranging from 8- to 14-folds dependent on the neural
pathways. The high efficiency of gene transfer was also detected in the brain regions that
project to the nucleus accumbens or medial prefrontal cortex in mice. In addition, we ob‐
served gene transduction of the HiRet vector into glial cells (~75%) and a small number of
neuronal cells (~20%) in the striatum around the injection sites (Fig. 2C). Recently, we creat‐
ed a variant of FuG-B (termed FuG-B2), in which the extracellular and transmembrane do‐
mains of RV-G derived from the challenged virus standard strain was exchanged with the
counterparts of Pasteur virus strain, and the vector pseudotyped with FuG-B2 exhibited a
further increase in the retrograde gene transfer efficiency in the rodent brain (Kato et al.,
2011b). More recently, Carpentier et al. (2012) reported the increased psudotyping efficiency
of an HIV-1 vector by a chimeric envelope glycoprotein composed of RV-G and VSV-G do‐
mains, which corresponds to our FuG-B.
The  host  range  of  lentiviral  vectors  is  altered  by  pseudotyping  with  different  envelope
glycoproteins (Cronin et al., 2005). Therefore, the possibility arises that some mutations in
RV-G shift the efficiency of gene transduction or host cell specificity of the pseudotyped
vector.  Indeed,  substitution of  the cytoplasmic domain of  RV-G with the corresponding
part  of  the  VSV-G enhanced the efficiency of  retrograde gene transfer.  The cytoplasmic
domain differs in length between RV-G (44 amino acids) and VSV-G (29 amino acids), but
their amino acid sequences do not show any particular homology (Rose et al., 1982). It ap‐
pears that the cytoplasmic domain is involved in the mechanism underlying vector entry
into synaptic terminals or the transduction level of the vector, resulting in enhanced retro‐
grade gene transfer.
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Figure 2. Gene trasnfer by HiRet vector. (A)Fusion envelope glycoprotein. The structure of viral envelope glycoprotein
is schematically illustrated in the left panel. FuG-B is composed of the extracellular and transmembrane (TM) domains
of RV-G derived from the challenge virus standard (CVS) strain fused to the cytoplasmic domain of VSV-G. In FuG-B2,
the RV-G domains are exchanged by the counterparts of RV-G derived from Pasteur virus (PV) strain. S, signal peptide.
(B) Gene transfer through retrograde transport. The HiRet vector pseudotyped with FuG-B, encoding GFP transgene
was injected into the mouse striatum. Four weeks later, sections were processed for GFP immunostaining (right pan‐
el). GFP expression can be seen in the brain regions innervating the striatum, including the M1, S1, PF, and SNc. (C)
Gene transduction around the injection sites. Sections through the striatum were stained by double immunofluores‐
cence histochemistry for GFP/NeuN or for GFP/glial fibrillary acidic protein (GFAP). Scale bars: 50 μm. (Data from Kato
et al., 2011a)
2.2. NeuRet vector
The NeuRet vector is another pseudotype of the HIV-1 lentiviral vector with FuG-C, which
is composed of the N-terminal segment of the extracellular domain (439 amino acids) of RV-
G and the C-terminal segment of the extracellular domain (16 amino acids) and transmem‐
brane/cytoplasmic domains of VSV-G (Fig. 3A) (Kato et al., 2011c). After injection of the
NeuRet vector encoding GFP transgene into the mouse striatum, we found enhanced retro‐
grade gene transfer into the brain regions innervating the striatum, such as the M1, S1, PF,
and SNc (Fig. 3B). The efficiency of gene transfer of the NeuRet vector was slightly different
with that of the HiRet vector (FuG-B2 pseudo type), depending on the neural pathways (see
a review by Kato et al. 2012). In addition, we tested gene transduction of the NeuRet vector
surrounding the injection sites. Although the NeuRet vector transduced only a small num‐
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ber of striatal neuronal cells (~6%), its transduction level into striatal glial cells was quite low
(~0.3%) (Fig. 3C). The property of gene transduction of the NeuRet vector around the injec‐
tion sites was quite different from that of the HiRet vector, and in particular, the transduc‐
tion of glial cells was largely declined in the NeuRet vector. Furthermore, when the NeuRet
vector was injected into the subventricular zone, gene transduction of the vector into neural
stem/progenitor cells was also inefficient.
FuG-C pseudotyping of the NeuRet vector enhanced the efficiency of retrograde gene trans‐
fer into various neuronal populations, whereas it caused less efficiency of gene transduction
into glial and neural stem/progenitor cells. The N-terminal segment of the RV-G extracellu‐
lar domain of 439 amino acids appears to be involved in the retrograde gene transfer, proba‐
bly by promoting the interaction with synaptic terminals required for retrograde transport.
Actually, amino acid residues essential for rabies virus virulence are reported to exist in the
RV-G-derived extracellular domain used for FuG-C construction (Prehaud et al., 1988; Cou‐
lon et al., 1998). In contrast, pseudotyping with FuG-B (FuG-B2) and FuG-C generates a
marked difference in gene transduction into glial and neural stem/progenitor cells around
the injection areas. This difference suggests that the C-terminal part of 16 amino acids in the
extracellular domain of envelope glycoproteins may be implicated in determining the host
cell specificity of vector transduction, and that this C-terminal part may contribute to the in‐
teraction with glial and neural stem/progenitor cells.
For gene therapy trials with lentiviral vectors, there is a significant issue that vector inser‐
tion into the host genome may lead to tumorigenesis by altering the expression of cellular
oncogenes surrounding the integration sites (De Palma et al., 2005; Themis et al., 2005; Mon‐
tini et al., 2006). One useful approach to protect this issue is to restrict vector transduction to
neuronal cells. The NeuRet vector system provides a useful approach for gene therapy trials
for neurological diseases through enhanced retrograde gene transfer and improves the safe‐
ty of gene therapy by profoundly suppressing the efficacy of gene transduction into divid‐
ing cells in the brain.
3. Retrograde gene delivery into monkey nigrostriatal pathway by
NeuRet vector
The nigrostriatal dopamine system is a major target for gene therapy of Parkinson’s disease.
The availability of the HiRet vector for gene transfer via retrograde transport into the nigros‐
triatal dopamine system in nonhuman primates was described in our previous review (Kato
et al., 2011d). To verify the capability of the NeuRet vector for efficient retrograde gene
transfer into the nigrostriatal pathway, we injected the NeuRetvector encoding the GFP
transgene into the striatum (caudate nucleus and putamen) of crab-eating monkeys (Fig.
4A). Intrastriatal injection of the NeuRet vector produced a larger number of GFP-positive
neurons in the SNc (Fig. 4B). These positive signals were in register with immunostaining
for tyrosine hydroxylase, a marker of dopaminergic neurons (Fig. 4C), indicating the trans‐
gene expression in the nigrostriatal dopaminergic neurons. In addition, we assessed the
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property of gene transduction with the NeuRet vector around the injection sites in the mon‐
key striatum. The vector displayed a low level of gene transfer into neuronal cell bodies
(~13%), and the level of vector transduction into glial cells was also quite low in the monkey
striatum (~0.6%) (Fig. 4D).The pattern of gene transduction around the injection sites was
similar to that obtained from the analysis of the mouse brain sections. Therefore, the NeuRet
vector mediates enhanced retrograde gene transfer, whereas it reduces the gene transfer into
glial cells around the injection areas in both rodent and monkey brains.
Figure 3. Gene delivery by NeuRet vector. (A) Structure of fusion envelope glycoprotein. FuG-C is composed of the N-
terminal segment of the extracellular domain of RV-G and the C-terminal segment of the extracellular domain and the
transmembrane(TM)/cytoplasmic domains of VSV-G. Amino acid sequences around the junction between the RV-G
and VSV-G segments are shown. S, signal peptide. (B) Gene transfer through retrograde transport. The NeuRet vector
encoding GFP transgene was injected into the mouse striatum, and four weeks later sections were processed for GFP
immunostaining. GFP expression can be visualized in the M1, S1, PF, and SNc. (C) Gene transduction around the injec‐
tion sites. Sections through the striatum were stained by double immunofluorescence histochemistry for GFP/NeuN or
for GFP/glial fibrillary acidic protein (GFAP). Scale bars: 50 μm. (Data from Kato et al., 2011c)
The NeuRet vector system successfully achieved efficient gene transfer through retrograde
transport into the nigrostriatal dopaminergic neurons in nonhuman primates. Our vector
system will provide a powerful strategy for gene therapy of Parkinson’s disease with en‐
hanced retrograde gene transfer in the near future. This system will improve the safety of
gene therapy by reducing the risk of gene transduction into proliferating cells (glial and
neural stem/progenitor cells) in the brain.
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Figure 4. Transgene expression in the nigrostriatal dopamine system by NeuRet vector injection into the mon‐
key striatum. (A) Gene transfer through retrograde transport after intrastriatal injection. The NeuRet vector encoding
GFP transgene was stereotaxically injected into the caudate nucleus and the putamen, and histological analysis was
performed on the brains fixed at the 4-week postinjection period. (B) GFP immunostaining in the SNc.Cp, cerebral pe‐
duncle; SNr, substantia nigra pars reticulata. (C) Double immunofluorescence staining for GFP and tyrosine hydroxy‐
lase (TH) in the SNc. (D) Double immunofluorescence staining for GFP/NeuN or GFP/glial fibrillary acidic protein
(GFAP) in the striatum. Scale bars: 500 μm (B), and 50 μm (C, D). (Data from Kato et al., 2011c)
4. Conclusion
In this chapter, we mentioned the gene transduction property of the HiRet and NeuRet vec‐
tors pseudotyped with different fusion envelope glycoproteins. These two vectors showed
the enhancement in gene transfer through retrograde axonal transport into various neuronal
populations in both rodent and nonhuman primate brains. The HiRet vector transduced
prominently glial cells around the injection sites, whereas gene transduction of the NeuRet
vector into glial cells was much less efficient. The transduction level of the NeuRet vector
into neural stem/progenitor cells was also low. The variation in the structure of envelope
glycoproteins shifted the efficiency of retrograde gene transfer and the preference of host
range. In addition, we described the application of the NeuRet vector for retrograde gene
transfer into the nigrostriatal dopamine system of monkeys. The NeuRet vector, together
with the HiRet vector, will offer a promising technology for gene therapy of neurological
diseases through enhanced retrograde gene transfer. In particular, the NeuRet vector system
will improve the safety of gene therapy by greatly suppressing the risk of gene transduction
into dividing cells in the central nervous system.
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